Macrozyme

Macrozyme is a Dutch biotechnology company specializing in the development of innovative tools and therapeutic leads for lysosomal storage disorders and related neurodegenerative conditions. Founded as a spin-off from the University of Amsterdam and the Academic Medical Center, the company leverages a proprietary platform based on Activity-Based Probes (ABPs) to monitor enzyme activity in vivo and in vitro. Their research primarily focuses on the glycobiology of sphingolipids, targeting enzymes such as glucosylceramide synthase and glucocerebrosidase. Macrozyme's technology has been instrumental in the discovery of small molecule modulators for diseases like Gaucher disease and Parkinson's disease. The company's work has laid the foundation for further clinical development through partnerships and spin-off entities like Azafaros.